
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc is poised for positive growth due to strategic transactions that enhance its clinical updates and broaden its options, especially ahead of significant clinical readouts. The company's promising pipeline, particularly with VK2735, which offers a potential monthly dosing regimen, along with the anticipated amylin agonist IND, positions it favorably for lucrative partnerships and financing opportunities. Furthermore, Viking's advanced stage and strong data relative to its peers potentially increase its attractiveness to investors, magnifying the company's value in an increasingly competitive metabolic market.
Bears say
Viking Therapeutics Inc. faces significant challenges characteristic of the biopharmaceutical industry, including the potential for unexpected clinical trial outcomes and regulatory uncertainty that could adversely impact its development pipeline. The company is also navigating increasingly complex and price-sensitive commercial markets, which add to the risk associated with its product candidates, VK2809, VK5211, and VK0214. Additionally, the heightened scrutiny surrounding US/China licensing deals may further complicate its operational environment, introducing additional uncertainty to its financial outlook.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares